PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS

被引：0
|
作者：
Patel, M. [1 ]
Hutchaleelaha, A. [1 ]
Siu, V. [1 ]
Silva-Garcia, A. [1 ]
Oksenberg, D. [1 ]
Lehrer-Graiwer, J. [2 ]
Mant, T. [3 ]
Ramos, E. [2 ]
机构：
[1] Global Blood Therapeut, Biol, San Francisco, CA USA
[2] Global Blood Therapeut, Clin, San Francisco, CA USA
[3] Guys Hosp, Quintiles Drug Res Unit, London, England
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P370
引用
收藏
页码：124 / 125
页数：2
相关论文
共 25 条
  • [1] Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S ( HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease ( SCD), in Healthy Male Subjects
    Rademacher, Peter
    Hutchaleelaha, Athiwat
    Washington, Carla
    Lehrer, Josh
    Ramos, Eleanor
    BLOOD, 2016, 128 (22)
  • [2] THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)
    Washington, C.
    Savic, R.
    Inati, A.
    Estepp, J.
    Woods, G.
    Fong, E.
    Hutchaleelaha, A.
    Tonda, M.
    Balaratnam, G.
    Lehrer-Graiwer, J.
    HAEMATOLOGICA, 2017, 102 : 244 - 244
  • [3] The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)
    Washington, Carla B.
    Green, Michelle
    Inati, Adlette C.
    Brown, Clark
    Hoppe, Carolyn C.
    Wang, Winfred
    Balaratnam, Ganesh
    Dixon, Sandra
    Fong, Erica
    Hutchaleelaha, Athiwat
    Tonda, Margaret E.
    Lehrer, Josh
    BLOOD, 2017, 130
  • [4] Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
    Hutchaleelaha, Athiwat
    Patel, Mira
    Washington, Carla
    Siu, Vincent
    Allen, Elizabeth
    Oksenberg, Donna
    Gretler, Daniel D.
    Mant, Timothy
    Lehrer-Graiwer, Josh
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1290 - 1302
  • [5] A Single Center Experience of GBT440 Treatment of Severe Anemia in Sickle Cell Disease (SCD)
    Bridges, Kenneth R.
    Gershwin, Blyden
    Bronte, Lanetta
    BLOOD, 2017, 130
  • [6] Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
    Lehrer-Graiwer, Josh
    Howard, Jo
    Hemmaway, Claire Jane
    Awogbade, Moji
    Telfer, Paul
    Layton, Mark
    Porter, John B.
    Mant, Timothy
    Dufu, Kobina
    Hutchaleelaha, Athiwat
    Oksenberg, Donna
    Patel, Mira
    Tonda, Margaret Eleanor
    Bridges, Kenneth
    Ramos, Eleanor
    BLOOD, 2016, 128 (22)
  • [7] The 10-Item Sickle Cell Disease Severity Measure (SCDSM-10): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
    Burke, Laurie
    Hobart, Jeremy Charles
    Fox, Kathleen
    Lehrer-Graiwer, Josh
    Bridges, Kenneth
    Kraus, Martine
    Ramos, Eleanor
    BLOOD, 2016, 128 (22)
  • [8] GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers
    Brown, R. Clark Clark
    Redfern, Andrew
    Lisbon, Eleanor
    Washington, Carla
    Agodoa, Irene
    Smith-Whitley, Kim
    BLOOD, 2021, 138
  • [9] Hemoglobin S (HbS) polymerization inhibitor Treatment of sickle cell disease
    Singh, A.
    DRUGS OF THE FUTURE, 2019, 44 (12) : 933 - 941
  • [10] Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor
    Hoppe, Carolyn C.
    Inati, Adlette C.
    Brown, Clark
    Wang, Winfred
    Gordeuk, Victor R.
    Liem, Robert
    Woods, Gerald
    Piccone, Connie M.
    Fong, Erica
    Balaratnam, Ganesh
    Dixon, Sandy
    Tonda, Margaret E.
    Washington, Carla B.
    Yaron, Yifah
    Lehrer, Josh
    BLOOD, 2017, 130
123